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Cancer invasion and metastasis have been likened to wound healing gone awry. Despite parallels in cellular behavior
between cancer progression and wound healing, the molecular relationships between these two processes and their
prognostic implications are unclear. In this study, based on gene expression profiles of fibroblasts from ten anatomic
sites, we identify a stereotyped gene expression program in response to serum exposure that appears to reflect the
multifaceted role of fibroblasts in wound healing. The genes comprising this fibroblast common serum response are
coordinately regulated in many human tumors, allowing us to identify tumors with gene expression signatures
suggestive of active wounds. Genes induced in the fibroblast serum-response program are expressed in tumors by the
tumor cells themselves, by tumor-associated fibroblasts, or both. The molecular features that define this wound-like
phenotype are evident at an early clinical stage, persist during treatment, and predict increased risk of metastasis and
death in breast, lung, and gastric carcinomas. Thus, the transcriptional signature of the response of fibroblasts to
serum provides a possible link between cancer progression and wound healing, as well as a powerful predictor of the
clinical course in several common carcinomas.
Introduction
Since the classic observations of the many histologic
similarities between the tumor microenvironment and
normal wound healing, it has been proposed that tumor
stroma is ‘‘normal wound healing gone awry’’ (Dvorak 1986).
During normal wound healing, coagulation of extravasated
blood initiates a complex cascade of signals that recruit
inflammatory cells, stimulate fibroblast and epithelial cell
proliferation, direct cell migration, and induce angiogenesis
to restore tissue integrity. Many of these normally reparative
processes may be constitutively active in the tumor milieu
and critical for tumor engraftment, local invasion, and
metastasis to distant organs (Bissell and Radisky 2001).
Indeed, keratinocytes from the wound edge transiently
exhibit many similarities to their transformed counterparts
in squamous cell carcinomas (Pedersen et al. 2003). Epide-
miologically, chronic wound and inflammatory states are
well-known risk factors for cancer development: the con-
nection between cirrhosis and liver cancer, gastric ulcers and
gastric carcinoma, and burn wounds and subsequent squa-
mous cell carcinoma (so-called Majorlin’s ulcer) are but a few
examples. In the genetic blistering disorder recessive dystro-
phic epidermolysis bullosa, nearly 80% of the patients
develop aggressive squamous cell carcinoma in their lifetime
(Mallipeddi 2002), attesting to the powerful inductive
environment of wounds for cancer development. In recent
years, the roles of angiogenesis, extracellular matrix remod-
eling, and directed cell motility in cancer progression have
been intensely studied (Bissell and Radisky 2001). Nonethe-
less, a comprehensive molecular view of wound healing and
its relationship to human cancer is still lacking. Thus, there is
currently no established method to quantify the risk of cancer
from wounds diagnostically or to intervene therapeutically.
The complete sequence of the human genome and the
advent of microarray technology have spurred a revolution in
the classification and diagnosis of human cancers (Golub et al.
1999; Alizadeh et al. 2000; Perou et al. 2000; Sorlie et al. 2001;
van ’t Veer et al. 2002; Ramaswamy et al. 2003). By detailing
the expression level of thousands of genes simultaneously in
tumor cells and their surrounding stroma, gene expression
profiles of tumors can provide ‘‘molecular portraits’’ of
human cancers. The variations in gene expression patterns in
human cancers are multidimensional and typically represent
the contributions and interactions of numerous distinct cells
and diverse physiological, regulatory, and genetic factors.
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Although gene expression patterns that correlate with
different clinical outcomes can be identified from microarray
data, the biological processes that the genes represent and
thus the appropriate therapeutic interventions are generally
not obvious. In this study, we explore an alternative strategy
to infer physiologic mechanisms in human cancers. We began
with a gene expression profile derived from a cell culture
model of a physiological process. The in vitro expression
profile is used to guide interpretation of publicly available
gene expression data from human cancers and thereby test a
specific hypothesis. In principle, this strategy allows one to
connect the controlled and dynamic molecular perturbations
possible in vitro with the complex biology of human clinical
samples in a comprehensive and quantitative fashion.
Fibroblasts are ubiquitous mesenchymal cells in the stroma
of all epithelial organs and play important roles in organ
development, wound healing, inflammation, and fibrosis.
Fibroblasts from each anatomic site of the body are differ-
entiated in a site-specific fashion and thus may play a key role
in establishing and maintaining positional identity in tissues
and organs (Chang et al. 2002). Tumor-associated fibroblasts
have previously been shown to promote the engraftment and
metastasis of orthotopic tumor cells of many epithelial
lineages (Elenbaas and Weinberg 2001). We previously
observed that the genomic response of foreskin fibroblasts
to serum, the soluble fraction of coagulated blood, represents
a broadly coordinated and multifaceted wound-healing
program that includes regulation of hemostasis, cell cycle
progression, epithelial cell migration, inflammation, and
angiogenesis (Iyer et al. 1999). We hypothesized that if one
could identify a canonical gene expression signature of the
fibroblast serum response, this signature might provide a
molecular gauge for the presence and physiologic signifi-
cance of the wound-healing process in human cancers.
Results
Identification of a Stereotyped Genomic Response of
Fibroblasts to Serum
We previously observed that the global transcriptional
response of fibroblasts to serum integrates many processes
involved in wound healing (Iyer et al. 1999). Because
fibroblasts from different anatomic sites are distinct differ-
entiated cells with characteristic gene expression profiles
(Chang et al. 2002), we investigated whether the genomic
responses to serum varied significantly among fibroblasts
cultured from different anatomic sites. Fifty fibroblast
cultures derived from ten anatomic sites were cultured
asynchronously in 10% fetal bovine serum (FBS) or in media
containing only 0.1% FBS. Analysis of the global gene
expression patterns, using human cDNA microarrays con-
taining approximately 36,000 genes, revealed that although
fibroblasts from different sites have distinctly different gene
expression programs, they share a stereotyped gene expres-
sion program in response to serum (Figure 1A). Selection for
genes that were concordantly induced or repressed by most
types of fibroblasts yielded 677 genes, represented by 772
cDNA probes, of which 611 are uniquely identified by
UniGene (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db
= unigene). This common genomic response to serum
includes induction of genes that represent entry into and
progression through the cell cycle (e.g., E2F1, FOXM1,
PTTG1), induction of cell motility (e.g., CORO1C, FLNC),
extracellular matrix remodeling (LOXL2, PLOD2, PLAUR),
cell–cell signaling (SDFR1, ESDN, MIF), and acquisition of a
myofibroblast phenotype (e.g., TAGLN, TPM2, MYL6). Anal-
ysis of the public Gene Ontology (GO) annotation of the
fibroblast serum response genes confirmed a significant
enrichment of genes involved in cell proliferation, blood
coagulation, complement activation, secretory protein syn-
thesis, angiogenesis, and proteolysis, reflecting the diverse
roles that fibroblasts may play during wound healing (Work-
sheet 9 in Dataset S2).
One of the most consistent and important responses of
human cells to serum is proliferation. Abnormal cell
proliferation is also a consistent characteristic of cancer
cells, irrespective of any possible involvement of a wound-
healing response. We therefore sought to eliminate the
contributions of genes directly related to cell proliferation,
to improve the specificity of a genomic signature of the
fibroblast serum response. To identify features directly
related to cell cycle progression, we examined the expression
pattern of these 677 genes during the cell cycle (in HeLa cells)
(Whitfield et al. 2002). Despite the well-known role of serum
as a mitogen, only one-quarter (165 out of 677 genes) of the
fibroblast serum response genes showed periodic expression
during the cell cycle (Figure 1B). The majority of the genes
whose expression levels in fibroblasts showed the most
consistent response to serum exposure do not appear simply
to reflect cell growth or division; these 512 serum-responsive
and cell cycle-independent genes are operationally defined as
the fibroblast core serum response (CSR). Comparison of the
common fibroblast serum response with a detailed analysis of
the temporal program of gene expression following serum
exposure in foreskin fibroblasts confirmed that the cell cycle
genes and the CSR have distinct temporal profiles during
serum stimulation and are thus distinguishable biological
processes (Figure 1C).
Expression of Fibroblast CSR in Human Cancers
Because serum (as distinct from plasma and normal
extracellular fluid) is encountered in vivo only at sites of
tissue injury or remodeling and induces in fibroblasts a gene
expression response suggestive of wound healing, we rea-
soned that expression of fibroblast CSR genes in tumors
might gauge the extent to which the tumor microenviron-
ment recapitulates normal wound healing. We examined the
expression of genes comprising the fibroblast CSR in publicly
available microarray data from a variety of human cancers
and their corresponding normal tissues. To facilitate visual-
ization and analysis, we organized the gene expression
patterns and samples by hierarchical clustering (Eisen et al.
1998). Remarkably, we observed a predominantly biphasic
pattern of expression for the fibroblast CSR in diverse
cancers, including breast cancers, lung cancers, gastric
cancers, prostate cancers, and hepatocellular carcinoma.
Expression levels of genes that were activated by serum in
fibroblasts varied coordinately in tumors, and genes that were
repressed by serum in fibroblasts were mostly expressed in a
reciprocal pattern (Figure 2).
In each of the tumor types examined, the expression
pattern of the fibroblast CSR genes in normal tissues closely
approximated that seen in quiescent fibroblasts cultured in
the absence of serum (Figure 2). In prostate and hepatocel-
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lular carcinomas, all of the normal tissue samples had the
serum-repressed signature and almost all of the tumors had
the serum-induced signature, albeit with varying amplitude.
In breast, lung, and gastric carcinomas, the common
fibroblast serum response signature was clearly evident in
some of the tumors and apparently absent in others,
suggesting that a ‘‘wound-healing phenotype’’ was a variable
feature of these cancers. We therefore classified breast, lung,
and gastric cancer samples based on the pattern of expression
of the genes that comprise the fibroblast CSR.
Link between the Gene Expression Signature of Fibroblast
Serum Response and Cancer Progression
To investigate the stability and consistency of the serum
response signature in individual tumors and to explore its
clinical implications, we examined CSR gene expression in a
group of locally advanced breast cancers with extensive
clinical and molecular data (Perou et al. 2000; Geisler et al.
2001; Sorlie et al. 2001). As shown in Figure 3A, the
expression profiles of the CSR genes were biphasic, allowing
a natural separation of these tumors into two classes.
Interestingly, in 18 out of 20 paired tumor samples obtained
from the same patients before and after excisional biopsy and
chemotherapy, the CSR expression phenotypes were consis-
tent between the two samples. Thus, the wound-related
expression program appears to be an intrinsic property of
each tumor and not easily extinguished. In a set of 51 patients
with clinically matched disease and equivalent treatment
(Sorlie et al. 2001), primary tumors with the activated CSR
signature were significantly more likely to progress to
metastasis and death in a 5-y follow-up period (p = 0.013
and 0.041, respectively) (Figure 3B). Using an alternative
analytic approach, classifying each sample by the Pearson
correlation between tumor and fibroblast expression patterns
of the fibroblast CSR genes, also reproduced the identifica-
tion of two classes of samples with differing clinical outcomes
(Worksheet 2 in Dataset S2). A gene expression pattern
similar to the serum-activated program of fibroblasts is thus a
powerful predictor of prognosis. Other significant prognostic
factors in these same patients include tumor grade, estrogen
receptor status, and tumor subtype based on gene expression
profile (Geisler et al. 2001; Sorlie et al. 2001). Tumor stage,
lymph-node status, and p53 status were not statistically
significant predictors of survival in these patients (p = 0.13,
0.79, 0.05, respectively). A ‘‘basal-like’’ subtype of breast
cancer, characterized by molecular similarities of the tumor
cells to basal epithelial cells of the normal mammary duct and
associated with a particularly unfavorable prognosis (Sorlie et
al. 2001), was significantly associated with a gene expression
pattern resembling the fibroblast CSR: six of seven basal-like
breast cancers had the ‘‘serum-activated’’ gene expression
signature (p = 0.0075, Fisher’s exact test). Thus, the presence
or absence of the wound-like phenotype may be linked to
intrinsic features of the tumor cells.
We considered the possibility that the observed phenom-
enon may be simply a reflection of the number of fibroblasts
in tumor samples. Perhaps tumors that are infiltrative or
otherwise worrisome clinically would demand a wide margin
of excision that would include more fibroblasts in the
resultant samples. However, classification of breast cancers
using the top 1% most highly expressed fibroblast genes
Figure 1. Identification and Annotation of
a Common Serum Response in Fibroblasts
(A) The fibroblast common serum re-
sponse. Genes with expression changes
that demonstrate coordinate induction
or repression by serum in fibroblasts
from ten anatomic sites are shown. Each
row represents a gene; each column
represents a sample. The level of ex-
pression of each gene in each sample,
relative to the mean level of expression
of that gene across all the samples, is
represented using a red–green color
scale as shown in the key; gray indicates
missing data. Representative genes with
probable function in cell cycle progres-
sion (orange), matrix remodeling (blue),
cytoskeletal rearrangement (red), and
cell–cell signaling (black) are highlighted
by colored text on the right. Three fetal
lung fibroblast samples, cultured in low
serum, which showed the most divergent
expression patterns among these sam-
ples (in part due to altered regulation of
lipid biosynthetic genes [Chang et al.
2002]), are indicated by blue branches.
(B) Identification of cell cycle-regulated genes in the common serum response signature. The expression pattern of each of the genes in (A)
during HeLa cell cycle over 46 h after synchronization by double thymidine block is shown (Whitfield et al. 2002). Transit of cells through S and
M phases during the timecourse, verified by flow cytometry, is indicated below. Approximately one-quarter of genes demonstrate a periodic
expression patterns and are therefore operationally annotated as cell cycle genes; the remainder of the genes are used in further analyses to
define the CSR.
(C) Validation of annotation by temporal expression profiles. Timecourse of gene expression changes in a foreskin fibroblast culture after
shifting from 0.1% to 10% FBS is shown. Global gene expression patterns were determined using cDNA microarrays containing 36,000 genes;
genes whose transcript levels changed by at least 3-fold during the timecourse and those in (A) are displayed. The cell cycle genes identified in
the analysis illustrated in (B) were found to have a distinct temporal expression pattern with coordinate upregulation at 12 h.
DOI: 10.1371/journal.pbio.0020007.g001
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(which include a number of extracellular matrix genes and
have been previous observed as the ‘‘stroma signature’’
[Perou et al. 2000]) showed no relationship between the
generic fibroblast signature and clinical outcome (p = 0.75;
Worksheet 1 in Dataset S2). Thus, the prognostic value of the
fibroblast CSR likely reflects the physiologic state of the
tumor microenvironment and not just the number of
fibroblasts in tumor stroma. Similarly, although the mitotic
index is an established criterion of tumor grade, classification
of these tumors based on expression of cell cycle genes
(specifically, all S and G2/M phase genes identified by
Whitfield et al. [2002]) only had moderate prognostic value
(p= 0.08; Worksheet 1 in Dataset S2). This result also suggests
that the prognostic value of the fibroblast CSR is unlikely to
be accounted for by the incomplete annotation and removal
of genes representing cell growth or division.
To extend and validate these results, we tested the
prognostic power of the fibroblast CSR signature in inde-
pendent datasets and different kinds of human cancer (Figure
4). Using published DNA microarray data from a study of
gene expression patterns in a group of 78 early (tumor
smaller than 5 cm, stage I and IIA) breast cancer patients (van
’t Veer et al. 2002), we could segregate the patients into two
groups based on expression of the fibroblast CSR genes in the
biopsy samples. Tumors with the serum-induced signature
had a significantly increased risk of metastasis over 5 y (p =
0.00046) (Figure 4A). Multivariate Cox proportional hazard
analysis confirmed that the CSR classification is a significant
independent predictor (p = 0.009); the serum-induced gene
expression signature was associated with a 3.3-fold relative
risk of breast cancer metastasis within 5 y of diagnosis. In the
two breast cancer datasets examined, approximately 50% of
the CSR genes demonstrated significant differences in
expression between the activated and quiescent groups of
samples, but permutation and 10-fold balanced leave-one-out
analyses revealed that the correct classification can be
accomplished using as few as 6% of CSR genes (Worksheets
10–12 in Dataset S2). Thus, the expression pattern of the CSR
genes provides a robust basis for predicting tumor behavior.
Similarly, in analysis of published DNA microarray data from
62 patients with stage I and II lung adenocarcinomas
(Bhattacharjee et al. 2001), tumors with the serum-induced
signature were associated with significantly higher risk of
death compared to tumors with the serum-repressed signa-
ture (p = 0.021) (Figure 4B). These results suggest that
presence or absence of a wound-like phenotype in these
cancers, with its prognostic implication for their metastatic
potential, may be determined at an early stage in their
development. In a second, independent group of lung
adenocarcinomas of all stages (Garber et al. 2001), tumors
with the fibroblast serum-induced signature were associated
with a significantly worse prognosis (p = 0.0014) (Figure 4C).
A significant correlation between advanced stage and the
serum-induced signature was also apparent in this dataset.
Finally, in 42 patients with stage III gastric carcinomas, all
treated with gastrectomy alone (Leung et al. 2002), tumors
with the activated CSR signature were again associated with
shorter survival (p = 0.02) (Figure 4D). These results suggest
that a wound-healing phenotype, reflected in the expression
of a set of serum-inducible genes in fibroblasts, is strongly
linked to progression of diverse human carcinomas and can
provide valuable prognostic information even at an early
stage in the natural history of a cancer.
For many other cancers, simple stratification based on
expression of genes in the fibroblast CSR gene set is unlikely
to be predictive of outcome. The dramatic differences in
cellular composition and architecture among the tissues in
which cancers can arise may influence the role that a wound-
healing response can play in their progression. For example,
lymphoma cells proliferate in the specialized microenviron-
Figure 2. Survey of Fibroblast CSR Gene
Expression in Human Cancers
Expression patterns of available CSR
genes in over 500 tumors and corre-
sponding normal tissues were extracted,
filtered as described in Materials and
Methods, and organized by hierarchical
clustering. The response of each gene in
the fibroblast serum response is shown
on the right bar (red shows activated;
green shows repressed by serum). The
strong clustering of the genes induced or
repressed, respectively, in fibroblasts in
response to serum exposure, based solely
on their expression patterns in the
tumor samples, highlights their coordi-
nate regulation in tumors. The dendro-
grams at the top of each data display
represent the similarities among the
samples in their expression of the
fibroblast CSR genes; tumors are indi-
cated by black branches, normal tissue by
green branches.
DOI: 10.1371/journal.pbio.0020007.g002
PLoS Biology | http://biology.plosjournals.org February 2004 | Volume 2 | Issue 2 | Page 0209
Serum Response and Cancer Progression
ment of lymph nodes and bone marrow, and the ‘‘stromal’’
cells in the central nervous system, predominantly astrocytes
and microglia, are markedly different from those associated
with most epithelial tissues. Indeed, in our initial analysis, the
pattern of expression of the fibroblast CSR genes failed to
stratify the outcomes in diffuse large B-cell lymphoma
(Rosenwald et al. 2002), medulloblastoma (Pomeroy et al.
2002), and glioblastoma multiforme (M. Diehn and P. O.
Brown, unpublished data).
Histological Architecture of CSR Gene Expression in
Tumors
Both to validate the DNA microarray results and to
investigate the histological architecture of CSR gene expres-
sion in tumors, we examined the expression patterns of five
CSR genes implicated in extracellular matrix remodeling and
cell–cell interaction, using tissue microarrays containing
hundreds of breast carcinoma tissues. PLAUR, also known
as urokinase-type plasminogen activator receptor, is a well-
characterized receptor for matrix-degrading proteases that
has been implicated in tumor cell invasion (Blasi and
Carmeliet 2002; Sidenius and Blasi 2003). LOXL2 is a member
of a family of extracellular lysyl oxidases that modify and
cross-link collagen and elastin fibers (Akiri et al. 2003).
PLOD2 is a member of the lysyl hydroxylase family that plays
important roles in matrix cross-linking and fibrosis (Van Der
Slot et al. 2003). SDFR1, previously named gp55 and gp65,
encodes a cell surface protein of the immunglobulin super-
family that regulates cell adhesion and process outgrowth
(Clarke and Moss 1994; Wilson et al. 1996). ESDN is a
neuropilin-like cell surface receptor that was also previously
found to be upregulated in metastatic lung cancers (Koshi-
kawa et al. 2002). All five of these genes were included in the
fibroblast CSR gene set by virtue of their induction by serum
in fibroblasts (see Figure 1). Anti-PLAUR antibody is
commercially available and served as a positive control. We
prepared specific riboprobes for LOXL2 and SDFR1 and
generated affinity-purified anti-peptide antibodies to PLOD2
and ESDN to detect the predicted protein products. As shown
in Figure 5, PLAUR, LOXL2, PLOD2, and ESDN were not
detectably expressed in normal breast tissue; SDFR1 was
expressed at a low level in normal breast epithelial cells (n =
11). In contrast, all five genes were induced in a significant
fraction of invasive ductal carcinomas of the breast. As
previously reported (Costantini et al. 1996), PLAUR protein is
expressed in both tumor cells and peritumoral stroma (70 out
of 96, 73% positive) (Figure 5). PLOD2 protein and SDFR1
mRNA were detected in breast carcinoma cells and in a small
but consistent fraction of peritumor stroma cells (78 out of
100, 78% positive, and 55 out of 79, 70% positive,
respectively). ESDN protein was detected exclusively in breast
carcinoma cells (69 out of 112, 62% positive). In contrast,
Figure 3. Context, Stability, and Prognostic Value of Fibroblast CSR in
Breast Cancer
(A) Expression patterns of CSR genes in a group of breast carcinomas
and normal breast tissue previously described in Perou et al. (2000).
Genes and samples were organized by hierarchical clustering. The
serum response of each gene is indicated on the right bar (red shows
induced; green shows repressed by serum). Note the biphasic pattern
of expression that allows each tumor sample to be classified as
‘‘activated’’ or ‘‘quiescent’’ based on the expression of the CSR genes.
The previously identified tumor phenotype (color code) and p53
status (solid black box shows mutated; white box shows wild-type) are
shown. Pairs of tumor samples from the same patient, obtained
before and after surgery and chemotherapy, are connected by black
lines under the dendrogram. Two primary tumor–lymph node
metastasis pairs from the same patient are connected by purple lines.
(B) Kaplan–Meier survival curves for the two classes of tumors.
Tumors with serum-activated CSR signature had worse disease-
specific survival and relapse-free survival compared to tumors with
quiescent CSR signature. Similar results were obtained whether
performing classification using all breast tumors in this dataset or just
the 58 tumors from the same clinical trial (Sorlie et al. 2001).
DOI: 10.1371/journal.pbio.0020007.g003
Figure 4. Prognostic Value of Fibroblast CSR in Epithelial Tumors
Kaplan–Meier survival curves of tumors stratified into two classes
using the fibroblast CSR are shown for stage I and IIA breast cancer
(van ’t Veer et al. 2002) (A), stage I and II lung adenocarcinoma
(Bhattacharjee et al. 2001) (B), lung adenocarcinoma of all stages
(Garber et al. 2001) (C), and stage III gastric carcinoma (Leung et al.
2002) (D).
DOI: 10.1371/journal.pbio.0020007.g004
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LOXL2 mRNA was abundant in peritumoral fibroblasts
around invasive carcinomas (45 out of 106, 42% positive).
LOXL2 protein has been previously reported to be expressed
in normal mammary ducts and increased in invasive breast
carcinoma cells (Akiri et al. 2003). Our data suggest that
LOXL2 is primarily synthesized by peritumoral fibroblasts,
but may act on or in the vicinity of epithelial cells during
tissue remodeling. Collectively, these results suggest that the
pathophysiology represented by expression of the fibroblast
CSR genes in cancers represents a multicellular program in
which the tumor cells themselves, tumor-associated fibro-
blasts, and perhaps diverse other cells in the tumor micro-
environment are active participants.
Discussion
The remarkable ability of a single physiological fluid—
serum—to promote the growth and survival of diverse
normal and cancer cells in culture suggests that there may
be a conserved, programmed response to the molecular
signals that serum provides. In vivo, serum as a physiological
signal has a very specific meaning: cells encounter serum—the
soluble fraction of coagulated blood—only in the context of a
local injury. In virtually any tissue, a rapid, concerted
multicellular response, with distinct physiological exigencies
that evolve over minutes, hours, and days, is required to
preserve the integrity of the tissue and often the survival of
the organism. In response to a wound, many of the normal
differentiated characteristics of the cells in the wounded
tissue are temporarily set aside in favor of an emergency
response. In wound repair, as in cancer, cells that ordinarily
divide infrequently are induced to proliferate rapidly,
extracellular matrix and connective tissues are invaded and
remodeled, epithelial cells and stromal cells migrate, and new
blood vessels are recruited. In all these respects, a wound
response—and the characteristic physiological response to
serum—would appear to provide a highly favorable milieu for
cancer progression.
We defined a stereotyped genomic expression response of
fibroblasts to serum, which reflects many features of the
physiology of wound healing. When we examined the
expression of these genes in human tumors, we found strong
evidence that a wound-like phenotype was variably present in
many common human cancers (including many that are not
known to be preceded by chronic wounds) and was a
remarkably powerful predictor of metastasis and death in
several different carcinomas.
The proposed link between the fibroblast serum response
signature and cancer progression raises many questions for
additional studies. Perhaps most importantly, our results do
not allow us to distinguish whether the wound-like phenotype
has a functionally important role in tumor progression or
merely serves as a marker for the underlying propensity of a
cancer to progress and metastasize. However, at least three
genes induced in the fibroblast serum response, PLAUR,
LOXL2, and MIF, have been previously shown to increase
cancer invasiveness or angiogenesis in animal xenograft
models; each of these three genes has also been shown to
play an important role in wound healing (Akiri et al. 2003;
Nishihira et al. 2003; Sidenius and Blasi 2003). Thus, we are
inclined to believe that coordinate induction of a wound-
Figure 5. Histological Architecture of CSR Gene Expression in Breast
Cancer
Representative ISH of LOXL2 and SDFR1 and IHC of PLOD2,
PLAUR, and ESDN are shown (magnification, 2003). Panels for
LOXL2, PLAUR, PLOD2, and ESDN represent cores of normal and
invasive ductal breast carcinoma from different patients on the same
tissue microarray. Panels for SDFR1 demonstrate staining in adjacent
normal and carcinoma cells on the same tissue section. Arrows
highlight spindle-shaped stromal cells that stain positive for SDFR1
and PLOD2. No signal was detected for the sense probe for ISH or for
control IHC without the primary antibody.
DOI: 10.1371/journal.pbio.0020007.g005
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healing program in carcinomas contributes to tumor invasion
and metastasis.
Several potential mechanisms might contribute to the
wound-like gene expression pattern in cancers. In some
cancers, ongoing local tissue injury, resulting from growth
and dysfunctional behavior of the tumor cells, could
continuously trigger a normal wound-healing response. The
classic observation of deposited fibrin products in human
tumors is consistent with this model (Dvorak 1986). Inflam-
matory cells, presumably recruited by tissue disorder, may
amplify the wound response and contribute to tumor
invasion in part by expression of metalloproteinases (Cous-
sens et al. 2000; Daniel et al. 2003). The wound response
might also be initiated directly by signals from the tumor cells
(Fukumura et al. 1998), whose ability to activate an
inappropriate wound-healing response—favorable to cell
proliferation, invasion, and angiogenesis—might be strongly
selected during cancer progression. The possibility that
stromal cells might play a primary role in promoting a
wound-like phenotype in some cancers is raised by studies
showing that tumor-associated fibroblasts can enhance tumor
engraftment and metastasis in animal models (Elenbaas and
Weinberg 2001) and the demonstration in some cancers of
genotypic abnormalities in tumor-associated fibroblasts
(Kurose et al. 2002). Heterotopic interaction experiments,
genetic models, and cell-culture models should enable these
and other possible mechanisms to be investigated.
Our results illustrate the power of using gene expression
data from specific cells or physiological and genetic manip-
ulations to build an interpretive framework for the complex
gene expression profiles of clinical samples (Lamb et al. 2003).
Several prognostic models based on gene expression patterns
have previously been identified from systematic DNA micro-
array profiles of gene expression in human cancers. Some of
these prognostic gene expression profiles appear to reflect
the developmental lineage of the cancer cells (Alizadeh et al.
2000; Sorlie et al. 2001; Pomeroy et al. 2002), some appear to
reflect the activity of specific molecular determinants of
tumor behavior (e.g., the activity of PLA2G2A in gastric
cancer [Leung et al. 2002]), while still others represent the
mechanistically agnostic results of machine-assisted learning
(van ’t Veer et al. 2002; Ramaswamy et al. 2003). Although
they serve to identify many of the same tumors with
unfavorable prognosis, the genes that define the fibroblast
CSR overlap minimally with the genes previously used to
predict outcome in the same cancers. For example, the
fibroblast CSR involves only 20 out of 456 genes in an
‘‘intrinsic gene list’’ that can serve to segregate breast cancers
into prognostically distinct groups (Perou et al. 2000) and
four out of 128 genes that define the general metastasis
signature reported by Ramaswamy et al. (2003). Only 11 genes
are in common between the 231 gene van’t Veer poor
prognosis signature for breast cancer (van ’t Veer et al. 2002)
and the fibroblast CSR genes. The prognostic power of these
different sets of genes illustrates the multidimensional
variation in the gene expression programs in cancers and
the complex interplay of many distinct genetic and physio-
logical factors in determining the distinctive biology of each
individual tumor. Our success in discovering a significant new
determinant of cancer progression, using previously pub-
lished and publicly available data, illustrates the richness of
the data as a continuing source for future discoveries and the
importance of unrestricted access to published research data
(Roberts et al. 2001).
The signals and regulatory systems that normally initiate,
sustain, and eventually shut down the physiological response
to a wound remain to be identified and understood.
Identification of the molecular control mechanisms in this
pathway may pave the way to new cancer therapies or
chemopreventative agents. For example, cyclooxygenase 2 is
strongly induced in the response of fibroblasts to serum (Iyer
et al. 1999), and platelet-derived growth factor is one of the
principal molecular signals and mitogenic factors in serum.
Platelet-derived growth factor receptor and cyclooxygenase 2
are inhibited by imatinib mesylate and nonsteroidal anti-
inflammatory agents, respectively—two drugs with estab-
lished efficacy in treating or preventing cancer (Bergers et al.
2003; Huls et al. 2003). Whether these or other small
molecules might derive significant activity against cancer
from their ability to inhibit a dysregulated wound-healing
response will be an important question for future inves-
tigation.
Materials and Methods
Cells and tissue culture. Human primary fibroblasts from ten
anatomic sites were cultured in 0.1% versus 10% FBS, as previously
described (Chang et al. 2002). For the serum induction timecourse,
foreskin fibroblasts CRL 2091 (American Type Culture Collection
[ATCC], Manassas, Virginia, United States) were serum-starved for 48
h and harvested at the indicated timepoints after switching to media
with 10% FBS, essentially as described in Iyer et al. (1999).
Microarray procedures. Construction of human cDNA microarrays
containing approximately 43,000 elements, representing approxi-
mately 36,000 different genes, and array hybridizations were as
previously described (Perou et al. 2000). mRNA was purified using
FastTrack according to the manufacturer’s instructions (Invitrogen,
Carlsbad, California, United States). For the serum timecourse, RNA
from all of the sampled timepoints were pooled as reference RNA to
compare with RNA from individual timepoints as described in Iyer et
al. (1999).
Data analysis. For defining a common serum response program in
fibroblasts, global gene expression patterns in 50 fibroblast cultures
derived from ten anatomic sites, cultured in the presence of 10% or
0.1% FBS, were characterized by DNA microarray hybridization
(Chang et al. 2002). We selected for further analysis genes for which
the corresponding array elements had fluorescent hybridization
signals at least 1.5-fold greater than the local background fluores-
cence in the reference channel, and we further restricted our analyses
to genes for which technically adequate data were obtained in at least
80% of experiments. These filtered genes were then analyzed by the
multiclass Significance Analysis of Microarrays (SAM) algorithm
(Tusher et al. 2001) to select a set of genes whose expression levels
had a significant correlation with the presence of serum in the
medium, with a false discovery rate (FDR) of less than 0.02%. The
corresponding expression patterns were organized by hierarchical
clustering (Eisen et al. 1998). Genes that were coordinately induced or
repressed in response to serum in most samples (Pearson correlation,
greater than 90%) were identified. This set of 677 genes, represented
by 772 cDNA probes, of which 611 are uniquely identified by
UniGene (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db =
unigene), was termed the common fibroblast serum response gene
set. To identify the subset of these 677 genes whose variation in
expression was directly related to cell cycle progression, we compared
this set of genes to a published set of genes periodically expressed
during the HeLa cell cycle (Whitfield et al. 2002). Because both
datasets were generated using similar cDNA microarrays, we tracked
genes by the IMAGE number of the cDNA clones on the microarrays.
The majority of the genes in the fibroblast serum response gene set
showed no evidence of periodic expression during the HeLa cell
cycle. One hundred sixty-five genes, represented by 199 cDNA clones,
overlapped with the cell cycle gene list; the remaining 512 genes,
represented by 573 clones, of which 459 are uniquely identified in
UniGene, was termed the CSR gene set.
The patterns of expression in human tumors of the 512 genes of
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the fibroblast CSR gene set were analyzed using data from published
tumor expression profiles. Detailed methods and primary datasets are
available as Datasets S1 and S2 and on our Web site (http://
microarray-pubs.stanford.edu/wound). We used the Unigene unique
identifier (build 158, release date January18, 2003) to match genes
represented in different microarray platforms. For cDNA micro-
arrays, genes with fluorescent hybridization signals at least 1.5-fold
greater than the local background fluorescent signal in the reference
channel (Cy3) were considered adequately measured and were
selected for further analyses. For Affymetrix data, signal intensity
values were first transformed into ratios, using for each gene the
mean values of the normalized fluorescence signals across all the
samples analyzed as the denominators (Bhattacharjee et al. 2001). The
genes for which technically adequate measurements were obtained
from at least 80% of the samples in a given dataset were centered by
mean value within each dataset, and average linkage clustering was
carried out using the Cluster software (Eisen et al. 1998). In each set
of patient samples, the samples were segregated into two classes based
on the first bifurcation in the hierarchical clustering dendrogram.
For the datasets shown, the clustering and reciprocal expression of
serum-induced and serum-repressed genes in the tumor expression
data allowed two classes to be unambiguously assigned. Samples with
generally high levels of expression of the serum-induced genes and
low levels of expression of the serum-repressed genes were classified
as ‘‘activated’’; conversely, samples with generally high levels of
expression of serum-repressed genes and low levels of expression of
the serum-induced genes were classified as ‘‘quiescent.’’ Survival
analysis by a Cox–Mantel test was performed in the program Winstat
(R. Fitch Software).
In situ hybridization and immunohistochemistry. Digoxigenin-
labeled sense and antisense riboprobes for LOXL2 and SDFR1 were
synthesized using T7 polymerase-directed in vitro transcription
(Iacobuzio-Donahue et al. 2002). Sense and antisense riboprobes for
SDFR1 were made from nucleotides 51–478 of IMAGE clone 586731
(ATCC #745139), corresponding to the last 388 nucleotides of the 39
end of the coding sequence and 39 nucleotides of the 39 untranslated
region. Sense and antisense riboprobes for LOXL2 were made from
nucleotides 41–441 of IMAGE clone 882506 (ATCC #1139012),
corresponding to the 39 end of the coding sequence. In situ
hybridization (ISH) results were considered to have appropriate
specificity when we observed a strong, consistent pattern of hybrid-
ization of the antisense probe and little or no hybridization of the
corresponding sense probe.
Immunohistochemical (IHC) staining was performed using Dako
(Glostrup, Denmark) Envision Plus following the manufacturer’s
instructions. Anti-PLAUR antibody against whole purified human
uPA–receptor protein (AB8903; Chemicon, Temecula, California,
United States) was used at 1:200 dilution. Affinity-purified polyclonal
antibody to PLOD2 was produced by immunizing rabbits with
peptides EFDTVDLSAVDVHPN, coupled to keyhole limpet hemo-
cyanin (KLH) (Applied Genomics, Inc., Sunnyvale, California, United
States); affinity-purified antiserum was used for IHC at 1:25,000
dilution. Similarly, affinity-purified polyclonal antibody to ESDN was
produced by immunizing rabbits with peptide DHTGQENSWKPK-
KARLKK coupled to KLH (Applied Genomics, Inc.) and used for IHC
at 1:12,500 dilution. High-density tissue microarrays containing
tumor samples were constructed as described in Kononen et al.
(1998). ISH (Iacobuzio-Donahue et al. 2002) and IHC (Perou et al.
2000) were as reported. ISH and IHC images and data were archived
as described in Liu et al. (2002).
Supporting Information
Figure 1A can be interactively explored at http://microarray-
pubs.Stanford.edu/wound/. Raw datasets and all supporting data are
also available at http://microarray-pubs.stanford.edu/wound/.
Dataset S1. Detailed Bioinformatic Methods
Provides a description of microarray datasets, cross-platform map-
ping and data normalization, classification of cancers by fibroblast
CSR genes and correlated clinical outcomes (Worksheets 1–8 in
Dataset S2), the top 1% fibroblast genes in breast cancer prognosis
(see Worksheet 1 in Dataset S2), cell cycle S and G2/M genes in breast
cancer prognosis (see Worksheet 1 in Dataset S2), analysis of GO
annotations of fibroblast serum response genes (see Worksheet 9 in
Dataset S2), and the minimum number of CSR genes necessary for
tumor classification (see Worksheets 10–12 in Dataset S2).
Found at DOI: 10.1371/journal.pbio.0020007.sd001 (120 KB DOC).
Dataset S2. Supporting Data
Excel Worksheets of clinical and microarray data, as described in
Dataset S1.
Found at DOI: 10.1371/journal.pbio.0020007.sd002 (736 KB XLS).
Accession Numbers
The Locus Link (http://www.ncbi.nlm.nih.gov/LocusLink/) accession
numbers for the genes discussed in this paper are CORO1C (Locus
Link ID 23603), E2F1 (Locus Link ID 1869), ESDN (Locus Link ID
131566), FLNC (Locus Link ID 2318), FOXM1 (Locus Link ID 2305),
LOXL2 (Locus Link ID 4017),MIF (Locus Link ID 4282), MYL6 (Locus
Link ID 4637), PLAUR (Locus Link ID 5329), PLOD2 (Locus Link ID
5352), PTTG1 (Locus Link ID 9232), SDFR1 (Locus Link ID 27020),
TAGLN (Locus Link ID 6876), and TPM2 (Locus Link ID 7169).
The accession numbers of the Gene Ontology (GO) (http://www.
geneontology.org/) terms that appear in Dataset S1 are angiogensis
(GO:0001525), blood coagulation (GO:0007596), complement activa-
tion (GO:0006956), immune response (GO:0006955), N-linked glyco-
sylation (GO:0006487), protein translation (GO:0006445), and
proteolysis and peptidolysis (GO:0006508).
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